CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 13-263/S-082

APPROVAL LETTER
NDA 13-263/SCM-082

Hoffmann-La Roche Inc.
Attention: Ms. Christine Hoogmoed
Drug Regulatory Affairs
340 Kingsland Street
Nutley, NJ 07110-1199

Dear Ms. Hoogmoed:

Please refer to your supplemental new drug application dated November 20, 2000, received November 21, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Valium, Oral tablets 2 mg, 5 mg, and 10 mg.

This "Changes Being Effect in 30 days" supplemental new drug application provides for a change in the process to add a (b)(4)-----------------------------------------------
(b)(4)------

We have completed the review of this supplemental application, and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Anna Marie Homonnay, R.Ph., Regulatory Project Manager, at (301) 594-5535.

Sincerely,

(See appended electronic signature page)

Robert H. Seevers, Ph.D.
Chemistry Team Leader, Psychiatric Drugs for the
Division of Neuropharmacological Drug Products,
(HFD-120)
DNDC I, Office of New Drug Chemistry
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Robert H. Seevers
5/9/01 03:57:37 PM
CHEMIST REVIEW OF SUPPLEMENT

1. ORGANIZATION: HFD-120
2. NDA: 13-263
3. SUPPLEMENT NUMBERS/DATES: SCM-082
   Letter date: November 20, 2000
   Stamp date: November 21, 2000
4. AMENDMENTS/REPORTS/DATES: N/A
5. RECEIVED BY CHEMIST: December 1, 2000
Hoffman-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110-1199
Valium

8. NONPROPRIETARY NAME:
   Diazepam

9. CHEMICAL NAME/STRUCTURE:
   7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H1,4-
   benzodiazepin-2-one

10. DOSAGE FORM(S):
    Tablet
11. POTENCY:
    2 mg, 5 mg, 10 mg
12. PHARMACOLOGICAL CATEGORY:
    Anti-anxiety
13. HOW DISPENSED:
    X (Rx)  Yes  No
14. RECORDS & REPORTS CURRENT:
15. RELATED IND/NDA/DMF:
    N/A

SUPPLEMENT PROVIDES FOR: This CBE-30 provides for a change in the process to add a __________

Comments: The change was sought as several validation lots were observed to have __________

Conclusion: This supplement may be approved.
Reviewer's Signature

Team Leader

Christy S. John, Ph.D.

Robert H. Seevers, Ph.D.

DRAFT PORTION OF LETTER ATTACHED: YES___  NO X.

IND 60,019
HFD-120/CJohn
HFD-120/Division File
HFD-120/RSeevers
HFD-120/SHardeman
7 page(s) have been removed because it contains trade secret and/or confidential information that is not disclosable
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
----------------------
Christy John
5/4/01 01:58:56 PM
CHEMIST

Robert H. Seivers
5/8/01 12:01:17 PM
CHEMIST